[1] PANDY J G P, FRANCO P I G, LI R K. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials[J]. Support Care Cancer, 2022, 30(11):8655-8666. doi:  10.1007/s00520-022-07175-3
[2] BRAIK T, YIM B, EVANS A, et al. Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy[J]. J Community Support Oncol, 2014, 12(2):65-70. doi:  10.12788/jcso.0017
[3] HIROMOTO S, KAWASHIRI T, YAMANAKA N, et al. Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome[J]. Sci Rep, 2021, 11(1):8964. doi:  10.1038/s41598-021-88460-9
[4] DENG B, SUN W. Herbal medicine for hand-foot syndrome induced by fluoropyrimidines: a systematic review and meta-analysis[J]. Phytother Res, 2018, 32(7):1211-1228. doi:  10.1002/ptr.6068
[5] CARONIA D, MARTIN M, SASTRE J, et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome[J]. Clin Cancer Res, 2011, 17(7):2006-2013. doi:  10.1158/1078-0432.CCR-10-1741
[6] 王志鹏. 卡培他滨不良反应和耐药生物标志物的发现[D]. 上海: 中国人民解放军海军军医大学, 2019.
[7] WANG Z P, LI X X, YANG Y, et al. A sensitive and efficient method for determination of capecitabine and its five metabolites in human plasma based on one-step liquid-liquid extraction[J]. J Anal Methods Chem, 2019, 2019:1-10.
[8] FETY R, ROLLAND F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res. 1998, 4(9): 2039-2045.
[9] GAMELIN E, DELVA R, JACOB J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008, 26(13): 2099-105.
[10] MEZA-JUNCO J, SAWYER M B. Drug exposure: still an excellent biomarker[J]. Biomark Med, 2009, 3(6):723-731. doi:  10.2217/bmm.09.58
[11] DAHER ABDI Z, LAVAU-DENES S, PRÉMAUD A, et al. Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer[J]. Cancer Chemother Pharmacol, 2014, 73(6):1285-1293. doi:  10.1007/s00280-014-2466-0
[12] FISCHEL J L, FORMENTO P, CICCOLINI J, et al. Lack of contribution of dihydrofluorouracil and α-fluoro-β-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes[J]. Anti Cancer Drugs, 2004, 15(10):969-974. doi:  10.1097/00001813-200411000-00006
[13] YANG B X, XIE X R, LV D Z, et al. Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil[J]. Br J Cancer, 2023, 128(2):219-231. doi:  10.1038/s41416-022-02039-3
[14] 黎鹏, 王炳胜, 李永民. 卡培他滨诱导手足综合征动物模型的建立[J]. 中华肿瘤防治杂志, 2017, 24(12):802-807.
[15] DESMOULIN F, GILARD V, MALET-MARTINO M, et al. Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine[J]. Drug Metab Dispos, 2002, 30(11):1221-1229. doi:  10.1124/dmd.30.11.1221
[16] DESMOULIN F, GILARD V, MARTINO R, et al. Isolation of an unknown metabolite of capecitabine, an oral 5-fluorouracil prodrug, and its identification by nuclear magnetic resonance and liquid chromatography–tandem mass spectrometry as a glucuroconjugate of 5’-deoxy-5-fluorocytidine, namely 2’-(β-d-glucuronic acid)–5’-deoxy-5-fluorocytidine[J]. J Chromatogr B, 2003, 792(2):323-332. doi:  10.1016/S1570-0232(03)00319-2
[17] HE X Y, WANG J L, WANG Q, et al. P38 MAPK, NF-κB, and JAK-STAT3 signaling pathways involved in capecitabine-induced hand-foot syndrome via interleukin 6 or interleukin 8 abnormal expression[J]. Chem Res Toxicol, 2022, 35(3):422-430. doi:  10.1021/acs.chemrestox.1c00317